At PatientsCann UK, we represent the voices of patients who rely on safe, effective, and regulated access to medical cannabis. Since its legalisation in 2018, many people have continued to face unnecessary barriers to treatment, from stigma and misinformation to the limited availability of NHS prescriptions. For thousands of patients, private prescriptions remain the only viable route to accessing the medicine they need. That’s why the Department of Health and Social Care’s “Private (no...| PatientsCann UK
The Advisory Council on the Misuse of Drugs (ACMD) is reviewing cannabis-based products for medicinal use (CBPMs). The post PatientsCann UK Statement on the ACMD Review of Medical Cannabis first appeared on PatientsCann UK.| PatientsCann UK
PatientsCann UK has raised urgent concerns with both the UK and Republic of Ireland (ROI) governments over the risks faced by patients prescribed medicines that are classified as Schedule 1 Controlled Drugs in one jurisdiction but legally prescribed in the other. At present, a prescription issued in the UK, ROI or Crown Dependencies cannot be dispensed across the border if the medicine is considered Schedule 1. More critically, patients cannot lawfully carry these prescribed medicines across ...| PatientsCann UK
A brutally honest call-in to the UK medical cannabis patient community, about ego, division, and why we’re our own worst enemy. The post This Isn’t a Movement, It’s a Mess first appeared on PatientsCann UK.| PatientsCann UK
Network Rail’s policy breaches the Equality Act 2010. PatientsCann UK fights for fair treatment—take action now. The post Network Rail’s Response to Our Concerns: A Call for Fair and Transparent Policy first appeared on PatientsCann UK.| PatientsCann UK
Tetrahydrocannabinolic acid (THCa) is a non-psychoactive cannabinoid found abundantly in raw cannabis plants. Unlike its decarboxylated form, tetrahydrocannabinol (THC), THCa does not produce intoxicating effects. This distinction is crucial for medical cannabis patients, healthcare professionals, and industry experts seeking to understand the therapeutic potential and legal considerations of THCa, particularly within the United Kingdom. Biochemical Nature of THCa THCa serves as the acidic pr...| PatientsCann UK
Since the legalisation of medical cannabis in the UK in 2018, patients have faced numerous challenges in accessing and utilising cannabis-based medicinal products (CBMPs). Despite legal provisions, the landscape remains fraught with limited support, societal stigma, and complex legal hurdles. Organisations like Seed Our Future play a crucial role in advocating for patients’ rights and providing necessary support. Challenges in Legal Support The legal framework surrounding medical cannabis i...| PatientsCann UK
Medical cannabis patients in the UK who receive social care packages from their local authority can apply to have their cannabis-based prescription medicines (CBPM) costs assessed as Disability Related Expenditure (DRE). If accepted, this may reduce the costs of their social care charges but does not cover costs of the cannabis prescription. Understanding Social Care| PatientsCann UK - UK's Medical Cannabis Patient Organisation
At PatientsCann UK, we are deeply concerned by Network Rail’s recently issued safety advice (NRA24-13), which imposes a blanket ban on employees using prescribed medical cannabis outside the limited conditions recognised by NICE guidelines. This policy not only impacts employees’ health and livelihoods but also risks violating their rights under the Equality Act 2010. What| PatientsCann UK - Empowering Lives One Leaf At A Time
In this article, we explore the stigma associated with cannabis, the challenges faced by ethnic communities in the UK, and offer guidance for those seeking medical cannabis treatment. The post Ethnic Diversity in Cannabis: Navigating Stigma and Health Challenges first appeared on PatientsCann UK.| PatientsCann UK
